SI
LCTX icon

Sprott Inc’s Lineage Cell Therapeutics LCTX Stock Holding History

Sprott Inc’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$16.7K – 251
2025
Q4 		$16.7K Hold
10,000
– – ﹤0.01% 217
2025
Q3 		$16.9K Hold
10,000
– – ﹤0.01% 209
2025
Q2 		$9.07K Buy
+10,000
New +$5.93K ﹤0.01% 203

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sprott Inc's LCTX Position: Q1 2026 in Review

Sprott Inc sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 10,000 shares — an estimated $16.7K sold.

Sprott Inc first reported a position in LCTX in Q2 2025 and held it in 3 quarters. The position peaked at $16.9K in Q3 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Sprott Inc reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sprott Inc sold 10,000 Lineage Cell Therapeutics shares in Q1 2026, an estimated $16.7K.
  • Sprott Inc first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 3 quarters.
  • Sprott Inc's Lineage Cell Therapeutics position peaked at $16.9K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Sprott Inc's 13F filing for Q1 2026, filed 8 May 2026.